A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs). Other Scholarly Work (Faculty180)

cited authors

  • Johnson, Melissa Lynne; Yu, Helena Alexandra; Hart, Eric M; Worden, Rebekah; Rademaker, Alfred; Gupta, Rajesh; Miller, Claire; Patel, Jyoti D; Kris, Mark G; Miller, Vincent A; others

authors

publication date

  • 2012